natgillin/translations-raw huggingface dataset:
Use, combination, composition, compound or product as claimed in claim 22, wherein the bacterial infection is an infection with methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae or multiple resistant Enterococcus faecium. 
23. Uporaba, kombinacije, pripravka, spoja ili proizvoda prema zahtjevu 22, naznačena time da bakterijska infekcija je infekcija sa meticilin rezistentnom Staphilococcus aureus (MRSA), meticilin rezistentnim koagulaza-negativnim stafilokokom (MRCNS), penicilin rezistentnom Streptococcus pneumoniae ili višestruko rezistentnim Enterococcus Jfaecium.
at least one control unit (260) that controls at least one of the liquid spraying component (240), the flow control kit (252) and the liquid supply kit (250), 
- najmanje jednu upravljačku jedinicu (260) koja regulira namjanje jednu od komponente (240) raspršivanja tekućine, komplet (252) reguliranje protoka i komplet (250) dovoda tekućine,
Cyclization with a reagent such as diketene gives compound 2 which may be brominated with bromine in acetic acid, N-bromosuccinimide or other brominating agent to give compound 3. 
Cikliziranjem s reagensom poput diketena dobije se spoj 2, kojeg se može bromirati bromom u octenoj kiselini, N-bromsukcinimidom ili drugim sredstvom za bromiranje kako bi se dobilo spoj 3.
A nucleic acid encoding a polypeptide of claim 1. 
Izolirana nukleinska kiselina koja kodira Fc-fuzijski protein prema patentnim zahtjevima 1 do 6.
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol to give a compound of formula IIIb in the form of diastereomeric mixture (R,S+S,S) 
To m) reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom, da bi dobio spoj formule IIIb u obliku dijasteroizomerne smjese (R, S+8, S)
A continuous reaction process for the preparation Compound C of the formula from Compound B of the formula comprising oxidation of Compound B in a continuous reactor through which a solution of Compound B and hydrogen peroxide and an acid, while being cooled, are contacted as they continuously flow through the reactor. 
Postupak kontinuirane reakcije za pripremu Spoja C formule >->o o npoeTT: HR P2013099 T1 iz Spoja B formule koji obuhvaća oksidaciju Spoja B u kontinuiranom reaktoru kroz koji u doticaj dolaze otopina Spoja B i vodikov peroksid 1 kiselina, dok se istodobno hlade, i dok kontinuirano prolaze kroz reaktor.
The carrier peptide of claim 1, wherein each X is independently chosen from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and tyrosine, or wherein n is chosen from 4, 8, 12, 16, and 20, or wherein m is 1. 
Peptid nosač prema zahtjevu 1, naznačen time da svaki X je neovisno odabran od arginina, asparagina, asparaginske kiseline, glutaminske kiseline, glutamina, histidina, lizina, serina, treonina, i tirozina, ili pri čemu n je odabran od 4, 8, 12, 16, i 20, ili pri čemu mje 1.
Compounds according to claim 1 wherein: represents wherein A, R8 and R8' are as defined in claim 1. 
[image] predstavlja [image] pri čemu su A, R8 i R8' kako je definirano u patentnom zahtjevu 1.
is selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, and substituted or unsubstituted C4-C12 alkenynyl; 
je izabran od vodika, CORa, COORa, supstituiranog ili nesupstituiranog C2-C12 alkenila, supstituiranog ili nesupstituiranog C2-C12 alkinila i supstituiranog ili nesupstituiranog C4-C12 alkeninila;
The organic layer is separated, washed with water (2 x 100 ml), saturated sodium hydrogen carbonate solution (100 ml) and concentrated in vacuo to afford the titled compound as a pale yellow solid which is used crude in the next step. 
Organski sloj se odvoji, ispere s vodom (2 x 100 ml), sa zasićenom otopinom natrijevog hidrogen karbonata (100 ml) i koncentrira se u vakuumu, čime se dobije naslovni spoj kao blijeda žuta kruta tvar koju se koristi sirovu u slijedećem stupnju.
A combination of GPR119 agonist and DPP-IV inhibitor in accordance with the present invention is useful in treating or preventing diabetes and conditions related thereto. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist je selektivni GPRI19 agonist.
In one embodiment of the present invention, said method of therapy is a method of treatment or prevention of a cancer characterized by expression of the tumor-associated antigen of the present invention, in which the cancer is an esophageal tumor, an ovarian tumor, a head-neck tumor, a kidney tumor, a liver tumor, a lung tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, a stomach cancer, a pancreatic tumor, a renal cell carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-3 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je kancer - tumor pluća, tumor dojke, tumor prostate, melanom, tumor debelog crijeva, tumor želuca, tumor pankreasa, ORL tumor, karcinom renalnih stanica ili karcinom grlića materice, karcinom debelog crijeva ili karcinom dojke.
The method according to claim 28 wherein ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate is applied to an eye of the subject in need thereof, sequentially to the application of dorzolamide to the eye of the subject. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu se ((2R,3S,4R,5R)-5-(6- (ciklopentilamino)-9H-purin-9-11)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat i inhibitor - karboanhidraze primjenjuju topički kao jedna ili više kapi u oko subjekta.
I fig. 1 is shown a packaging 2 comprising an inner part with a first side 4 and a second side 6 interconnected by a hinging part 8. 
Na slici 1 je prikazano pakiranje 2 koje obuhvaća jedan unutarnji dio s prvom stranom 4 i drugom stranom 6 koje su međusobno povezane dijelom 8 koji predstavlja zglobni dio.
The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition comprises about 0.5 mg to about 1000 mg of crystalline Form B of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-11)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
assembling the first digested nucleic acid, the first joiner oligo, the second nucleic acid, and the second joiner oligo. 
povezivanje spojnog oligonukleotida sa prvom digestiranom nukleinskom kiselinom i drugom digestiranom nukleinskom kiselinom.
The kit of claim 1, comprising very low- or no-residue foods to be consumed up to two hours prior to the medical procedure. 
Komplet iz patentnog zahtjeva 1, sadrži hranu s vrlo malim ili nikakvim zaostacima koju treba unijeti najviše dva sata prije medicinskog postupka.
It is clear that this kind of management greatly enhances the control of the blood preservation, avoiding wanted or unwanted tampering, thereby providing a safer preservation. 
Jasno je da takva vrsta rada znatno povećava kontrolu čuvanja krvi i sprečava namjerno ili nenamjerno neovlašteno pristupanje i na taj način se provodi sigurnije čuvanje.
at least one arene; 
(iv) najmanje jednog arena;
A fan assembly as claimed in any of claims 12 to 18, wherein the air outlet (14) comprises a surface (42) located adjacent the mouth (40) and over which the mouth (40) is arranged to direct the air flow. 
Ventilatorski sustav prema bilo kojem zahtjevu 12 do 18, gdje izlaz zraka (14) iam površinu (42) smještenu uz usta (40) 1 preko koje su usta (40) smještena da usmjeravaju struju zraka.
A composition comprising the composition according to claim 5 and a pharmaceutically acceptable carrier or diluent. A method of treating a human subject suffering from a condition which is mediated by the action, or by loss of action, of Hepatitis B Virus (HBV), which comprises administering to said subject an effective amount of the double-stranded short interfering nucleic acid (siNA) molecule of claim 1, thereby treating the human subject suffering from a condition which is mediated by the action, or by loss of action, of HBV. 
Pripravak, naznačen time, da sadržava pripravak u skladu s patentnim zahtjevom 5 i farmaceutski prihvatljiv nosač ili razrjeđivač. Molekula s dvolančanom kratkom interferirajućom nukleinskom kiselinom (siNA) u skladu s patentnim zahtjevom 1, naznačena time, da se koristi u liječenju ljudskog subjekta koji pati od stanja koje je posredovano djelovanjem virusa hepatitisa B (HBV). Molekula za upotrebu u skladu s patentnim zahtjevom 7, naznačena time, da je navedeno stanje HBYV infekcija.
A compound of formula Y: wherein, R1 - R10 are independently hydrogen or deuterium, wherein R6-R10 are each deuterium, wherein at least one of R1-R10 comprises at least about 50% deuterium, or a pharmaceutically acceptable acid addition salt thereof. 
Spoj formule Y: pri čemu -R10 su nezavisno vodik ili deuterij, pri čemu su R6-R10 svaki deuterij, ili njegova farmaceutski prihvatljiva sol dobivena adicijom kiseline, za upotrebu kao lijek.
Thaw frozen membrane pellet on ice 
Otopi zamrznute pelete membrana na ledu.
may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and 
može biti alkil-skupina koja ima od jednoga do pet atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do pet atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od jednoga do tri atoma ugljika; i
hydrogenation of the amide obtained by catalytic palladium; 
hidrogeniranje dobivenog amida uz paladij kao katalizator,
The compound for use according to claim 1 or claim 2, wherein testing in step (b) occurs before or after treatment begins. 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što je učinkovita količina dnevna doza od 100 miligrama.
transcode an over-the-air, manufacturer-specific DMR Terminal registration into a SIP REGISTER message to result in the SIP Proxy server perceiving and managing the DMR Terminal as a SIP User Agent. 
REGISTER/REGISTRIRAJ poruku kako bi rezultirala _SIP proksi serverom koji prima i void _ DMR terminal kao SIP korisnički agent.
Step (i): reacting 4-hydroxy piperidine of formula (1) with cyclobutanone of formula (2) in presence of sodium triacetoxy borohydride in ethylene dichloride at a temperature in the range of 20 °C to 30 °C for a period of 12 hours to 14 hours to obtain 1-cyclobutylpiperidin-4-ol of formula (3); 
Korak (i): reakcija 4-hidroksi piperidina iz formule (1) s ciklobutanonom iz formule (2) u prisutnosti natrij triacetoksi borohidrida u etilen dikloridu pri temperaturi u rasponu do 20 °C do 30 °C u trajanju od 12 sati do 14 sati da bi se dobio 1-ciklobutilpiperidin-4-ol iz formule (3);
A method according to claim 12 or claim 13 wherein the GPCR119 agonist has an EC50 of less than 10µM. 
Postupak u skladu sa zahtjevom 12 ili zahtjevom 13, naznačen time, da GPR119 agonist ima EC50 manji od 10 uM.
A compound selected from the group consisting of a compound of formula (I-A) or (I-B): 
HR P20190994 T1 PATENTNI ZAHTJEVI Spoj formule (I-A) ili (I-B):
The compound according to the above [1], or a salt or solvate thereof, wherein R3 is a cyano group or a halogen atom. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova sol ili solvat, naznačen time što je R* skupina cijano ili atom halogena.
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively, unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, the group being an ester, ether, acetale, carbonate, carbamate, phosphate, phosphonate, ketal, sulfate, or sulfonate, and salts thereof. 
Ra je vodik, Ci do C,> alkil, fenil koji nije supstituiran ili je supstituiran s C; do Cy2 alkilnom ili COR; acilnom skupinom; R; je vodik, C, do C,» nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s Cy do Cy alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
A pharmaceutical combination of Claim 33 wherein the combination of the compound of Claim 1 and the glucosidase inhibitor is administered in the same or separate oral dosage forms. 
Farmaceutski sastav Zahtjeva 33, naznačen time, da se kombinacija spoja Zahtjeva 1 i inhibitora glukozidaze unosi u istom ili odvojenim oblicima oralnih doza.
End 16 of conduit 14 could be in fluid communication with a plurality of nozzles 12. 
Kraj 16 cjevovoda 14 može biti povezan s više mlaznica 12.
The topical veterinary composition for use according to any one of claims 1 to 10 wherein the parasite is an endoparasite. 
Sastav za uporabu prema zahtjevu 11, naznačen time, da parazit je endoparazit.
The apparatus of claim 1 wherein the secondary nozzles are disposed below the gas distribution nozzles and are configured to inject fluid into the base of the sloped chute. 
Uređaj prema zahtjevu 4 ili 5 naznačen time što su sekundarne mlaznice smještene ispod mlaznica za distribuciju plina i konfigurirane su da ubrizgavaju tekućinu ili gorivo u česticama u bazu za dovod goriva.
an outlet (11) located laterally to the reactor for the product gas stream, and 
- izlaz (11), smješten bočno u odnosu na reaktor, za struju gotovog plina, i
The method of item 12, wherein the target cell is a human cell infected by a human pathogen, and the therapeutic specifically binds an epitope of the human pathogen. 
(Cc) humana stanica zaražena humanim patogenom, a terapijsko antitijelo se specifično vezuje za epitop humanog patogena; ili
An oral formulation according to claims 1-7 wherein the ocular neovascular disorder is a choroidal neovascular disorder or a retinal neovascular disorder. 
Upotreba u skladu s patentnim zahtjevima 15-22, naznačena time što neovaskularni poremećaj oka je neovaskularni poremećaj žilnice ili neovaskularni poremećaj mrežnice.
A crystalline polymorph comprising a compound of Formula I: characterized by a powder x-ray diffraction pattern with at least peaks at diffraction angles 2θ of 7.7°, 15.0°, and 18.8° ± 0.2. 
HO CI naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s u najmanju ruku maksimumima na difrakcijskim kutevima 26 od 7,7%, 15,0", te 18,8% + 0,2.
Pimobendan according to any one of the preceding claims, wherein the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril,benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat and spirapril. 
Pimobendan prema bilo kojem od prethodnih zahtjeva, naznačen time, da je ACE inhibitor odabran iz skupine koju čine omapatrilat, MDL100240, alacepril, benazepril, kaptopril, silazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lizinopril, perindopril, kvinapnil, ramipril, ramiprilat, saralazin acetat, temokapril, trandolapril, trandolaprilat, ceranapril, moeksipril, kvinaprilat i spirapril.
The method of claim 6, wherein the compound of formula (I) is a compound of formula (Ia): 
R, je zaštitna skupina, i gdje je spoj formule (I) je spoj formule (Ia):
The method according to claim 1, said composition further comprising a skin penetration enhancer. The method according to claim 23, wherein the skin penetration enhancer is selected from the group consisting of polyvalent aliphatic C2-C10 alcohols, polyalkylene glycols having C2-C4 alkylene groups, nonalkoxylated ethers of polyvalent aliphatic C2-C10 alcohols and polyalkylene glycols having C2-C4 alkylene groups, azones, terpenes, terpenoides, pyrrolidones, sulfoxides, and mixtures thereof. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, koja i dalje sadrži promotor prodiranja kroz kožu, naznačen time, što se je promotor prodiranja kroz kožu poželjno odabran iz skupine koja se sastoji od polivalentnih alifatskih C2-C19g alkohola, polialkilenskih glikola s C2-C4 alkilenskim grupama, nealkoksiliranih etera polivalentnih alifatskih C>-C;9 alkohola i polialkilenskih glikola s C2-C, alkilenskim grupama, azona, terpena, terpenoida, pirolidona, sulfoksida i njihovih smjesa, a najpoželjnije je dimetil sulfoksid.
The pharmaceutical composition according to claim1, wherein the third species of active agent particles comprises budesonide, and is suspended in the suspension medium at a concentration sufficient to provide a delivered dose of budesonide of from 30 to 240 µg per actuation of the metered dose inhaler. 
Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time što treća vrsta čestica aktivnog sredstva sadrži budezonid, te se suspendira se u mediju za suspenziju u koncentraciji dovoljnoj da se osigura isporučena doza budezonida od 30 do 240 µg po aktiviranju inhalatora s odmjerenom dozom.
4, with at least one of the mutations selected from the group consisting of amino acid E at position 1 being replaced by N, amino acid S at position 28 being replaced by N, amino acid S at position 31 being replaced by T, amino acid V at position 33 being replaced by L, amino acid D at position 34 being replaced by A, amino acid Y at position 49 being replaced by F, amino acid T at position 53 being replaced by N, amino acid Y at position 55 being replaced by A, amino acid L at position 89 being replaced by Q, and amino acid N at position 93 being replaced by Y. The indicated position numbers refer to the corresponding position of the sequence as represented by SEQ ID NOs. 
4, gdje se najmanje jednu od mutacija bira iz skupine koju čine aminokiselina Q na položaju 1, zamijenjena s N, aminokiselina S na položaju 28, zamijenjena s N, aminokiselina S na položaju 31, zamijenjena s 'T, aminokiselina V na položaju 33, zamijenjena s L, aminokiselina D na položaju 34, zamijenjena s A, aminokiselina Y na položaju 49, zamijenjena s F, aminokiselina T na položaju 53, zamijenjena s N, aminokiselina Y na položaju 55, zamijenjena s A, aminokiselina L na položaju 89, zamijenjena s Q, te aminokiselina N na položaju 93, zamijenjena SY.
Apparatus as claimed in claim 7 or 8, wherein the baseplate (100'') is provided with clip restraining members (105) for restraining lateral and vertical movement of the clips (7, 7'). 
Uređaj u skladu s patentnim zahtjevom 7 ili 8, kod kojega je temeljna ploča (100") snabdjevena s elementima za držanje držača (105) koji elementi ograničavaju bočno i vertikalno pomicanje držača (7, 7'),
contacting a GPR119 agonist in vitro with a vertebrate enteroendocrine cell or with a cell capable of secreting GIP; and 
(a) stavljanje u doticaj agonista GPR119 in vitro sa enteroendokrinom stanicom kralježnjaka ili stanice sposobne za GIP sekreciju; i
The method of claim 16 wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis. 
Kristalni oblik za primjenu ili sastav za primjenu prema zahtjevu 10., pri čemu upalna bolest crijeva znači Crohnova bolest ili ulcerozni kolitis.
The following compounds were synthesized according to the above procedure. 
Sljedeće spojeve sintetizira se postupkom opisanim gore. ž
In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje bipolarnih poremećaja.
In practice this product containing 250 µg of ET-743 is manufactured by freeze-drying 5 ml of solution containing ET-743, mannitol, phosphate buffer and water in a moulded vial. 
U praksi se ovaj proizvod koji sadrži 250 ug ET-743 proizvodi sušenjem zamrzavanjem 5 ml otopine koja sadrži ET- 743, manitol, fosfatni pufer i vodu u ukalupljenim ampulama.
The influenza virus strain that is associated with a pandemic outbreak and wherein the disease caused by these strains can be treated by the binding molecules, is selected from the group consisting of H1N1, H5N1, H5N2, H5N8, H5N9, H2-based viruses, and H9N2. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 6, naznačeni time da je navedeni soj virusa influence koji je povezan sa izbijanjem pandemije odabran iz skupine koja sadrži: HIN1, HSN1, H5N2, HSN8, HSN9, soj na osnovi H2, i H9N2.
The invention also concerns pharmaceutical compositions containing the novel salt and hydrates as well as methods for using them as DP-IV inhibitors, in particular for the prevention or treatment of Type 2 diabetes, obesity, and high blood pressure. 
Izum se također bavi farmaceutskim pripravcima koji sadržavaju novu sol i njene hidrate, kao i metode njihovog korištenja kao DP-IV inhibitora, posebno u prevenciji ili liječenju dijabetesa tipa 2, pretilosti, te visokog tlaka.
The antibody of claim 1, wherein said light chain variable region is a germline O12 / IgVk1-39*01 variable region. 
Protutijela sukladno patentnom zahtjevu 1, naznačeno time, da je navedena varijabilna regija lakog lanca varijabilna regija germinalne linije O12/1gVx 1-39*01.
means (r715-L1) for decoding the selectively time-deinterleaved L1 data for a Forward Error Correction, FEC by a Low Density Parity Check, LDPC, decoding scheme; and 
sredstva (r303) za dekodiranje podataka u paketima podatkovnih komada za unaprijedno ispravljanje pogrešaka, FEC pomoću LDPC sheme za dekodiranje; i sredstva (r715-C) za vanjsko dekodiranje LDPC dekodiranih podataka.
The method for producing a panel as claimed in claim 8, further characterized by wholly coating the bottom of said formwork with a layer of non-woven fabric or equivalent sealing means. 
Postupak za izradu ploče prema prethodnim zahtjevima, naznačen time što se vrši kompletnim oblaganjem donje strane spomenutog okvira slojem netkanog tekstilnog materijala ili ekvivalentne barijere.
Glucose isomerase for use according to claim 1, wherein the therapy comprises reducing or preventing the occurrence of fructose intolerance symptoms in a human or animal subject after the intake by the said subject of fructose or a substance or foodstuff containing fructose in pure form or from which fructose can be released in the digestive tract. 
Glukoza izomeraze za uporabu u skladu sa zahtjevom 1, naznačena time, što liječenje obuhvaća smanjenje ili sprečavanje pojave simptoma intolerancije fruktoze kod subjekata čovjeka ili životinje nakon unosa navedenog subjekta fruktoze ili supstance ili prehrambenog proizvoda koji sadrži fruktozu u čistom obliku ili obliku od kojih fruktoza može biti puštena u probavni trakt.
A patch pipette made from borosilicate glass tubing (GC120F, Harvard Apparatus) using a P-97 micropipette puller (Sutter Instrument Co.) was filled with pipette solution (see hereinafter). 
Patch pipeta, izrađena od borosilikatne staklene cijevčice (GC120F, Harvard Apparatus) pomoću uređaja za izradu nikropipeta P-97 (Sutter Instrument Co.), napunjena je otopinom za pipetu (vidjeti daljnji tekst).